Skip to main content
TipRanks
Go Ultimate75% OFF

Sera Prognostics (SERA) AI Stock Analysis

109 Followers
SERA

Sera Prognostics

(NASDAQ:SERA)

Select Model
Rating:53Neutral
Price Target:$2.00â–²(0.00% Upside)
Action:reiterated
Date:11/11/26

The score is held back primarily by weak financial performance (very small revenue base, heavy losses, and sustained cash burn). Offsetting that, the latest earnings call described strong commercialization momentum and meaningful reimbursement progress with Medicaid coverage in two states plus a stated cash runway into FY2029. Technicals and valuation are neutral-to-weak, with shares trading below key moving averages and a negative P/E reflecting lack of profitability.

Positive Factors
Medicaid ReimbursementState Medicaid coverage creates a durable reimbursement pathway for PreTRM and materially expands the reachable patient base. The newly covered lives can support repeat utilization and provide a foundation for broader payer adoption as Sera demonstrates clinical and economic value.
Negative Factors
Persistent LossesThe very small and volatile revenue base remains far below the company’s cost structure, while negative gross profit and large operating losses show that scale has not yet been achieved. Sustained losses could delay self-funded growth until reimbursement converts into meaningful volume.

Sera Prognostics (SERA) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%SERA-36.10%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$77.60M
Dividend Yield
―
Average Volume (3M)
26.60K
Price to Earnings (P/E)
-2.9
Beta (1Y)
1.48
Revenue Growth
1.05%
EPS Growth
13.67%
Country
US
Employees
72
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Sera Prognostics Business Overview & Revenue Model

Company Description

Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay spe...

Sera Prognostics Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-0.74%|Next Earnings Date:Mar 24, 2027
Earnings Call SentimentPositive

The call was strongly positive, with substantial increases in ordering physicians and test volume, Medicaid coverage established in Illinois and Florida, expanding commercial and payer engagement, strengthening clinical and health economic evidence, and a stated cash runway into fiscal year 2029. The main challenges were lower third-quarter ASPs caused by a low- or non-reimbursed patient mix and the 12-month to 18-month timeframe typically required to move providers toward broad adoption. Management characterized the company as transitioning into commercialization with significant work still ahead.

Positive Updates

Strong PreTRM Commercial Momentum
Compared with the first quarter of 2026, the number of physicians ordering PreTRM nearly tripled and test volume increased approximately fivefold. Third-quarter test volume also increased 54% sequentially from the second quarter.

Negative Updates

Average Selling Price Declined
Average selling prices declined in the third quarter because a larger percentage of patients came from low- or non-reimbursed patient classes. Management expects this trend to begin reversing in fiscal year 2027 as the mix increasingly includes Medicaid patients in Florida and Illinois and paid commercial-pilot patients.

Company Guidance

Sera expects to pursue CE Mark approval for PreTRM Global in 2027, publish its PRIME health economic analysis in the fourth quarter, and see flat or down operating expenses in 2027 while significantly increasing the size of its commercial team; it believes it has sufficient cash to fund operations into fiscal year 2029. Management expects meaningful increases in product traction next calendar year, especially as it transitions to the second half of 2027, and is hoping at least 1 or 2 additional states will enact Medicaid coverage in fiscal year 2027. In Illinois and Florida, management is hoping to achieve low single-digits percentage penetration in each state in the first year and quickly accelerating afterwards; at, let's say, 20%, 30% of each state, revenue could be in tens of millions of dollars.

Sera Prognostics Financial Statement Overview

Summary

Financials are weak overall: revenue is very small and volatile, gross profit is negative, and losses remain large (TTM EBIT about -$37M; net loss about -$33M). Cash burn is persistent (TTM operating cash flow about -$28.5M; free cash flow about -$29.0M), implying ongoing funding needs. The main offset is modest leverage (debt ~ $3.0M vs. equity ~ $52M), though equity has declined materially over time.

Income Statement

12Very Negative

Balance Sheet

58Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue96.00K81.00K77.00K306.00K268.00K82.00K
Gross Profit-99.00K-83.00K-5,00096.00K75.00K45.00K
EBITDA-32.65M-30.98M-32.04M-35.29M-43.37M-33.60M
Net Income-33.47M-31.93M-32.90M-36.24M-44.19M-35.01M
Balance Sheet
Total Assets79.98M101.93M72.58M95.44M116.33M147.03M
Cash, Cash Equivalents and Short-Term Investments44.09M39.20M46.24M49.08M82.70M105.11M
Total Debt3.27M2.34M840.00K1.86M2.83M128.00K
Total Liabilities27.54M26.52M24.77M25.28M17.39M8.46M
Stockholders Equity52.44M75.41M47.80M70.16M98.94M138.56M
Cash Flow
Free Cash Flow-28.99M-26.35M-15.29M-27.32M-35.40M-32.94M
Operating Cash Flow-28.50M-25.62M-14.19M-27.19M-34.61M-31.64M
Investing Cash Flow28.11M-28.50M11.74M438.00K5.55M-82.56M
Financing Cash Flow301.00K54.03M2.61M752.00K5,000159.59M

Sera Prognostics Technical Analysis

Technical Analysis SentimentNegative
Last Price2.00

Price Trends

50DMA2.04Negative
100DMA2.04Negative
200DMA2.06Negative

Market Momentum

MACD-0.01Positive
RSI47.86Neutral
STOCH23.66Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SERA, the sentiment is Negative. The current price of 2.00 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.04, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.86 is Neutral, neither overbought nor oversold. The STOCH value of 23.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SERA.

Sera Prognostics Risk Analysis

Sera Prognostics disclosed 73 risk factors in its most recent earnings report. Sera Prognostics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.If our strategic prioritization fails to achieve some or all of the expected benefits therefrom, our cash resources may not last as long as estimated and our business, results of operations, and financial condition could be materially and adversely affected.Q2, 2026
2.If our strategic prioritization fails to achieve some or all of the expected benefits therefrom, our cash resources may not last as long as estimated and our business, results of operations, and financial condition could be materially and adversely affected.Q1, 2026
3.Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.Q3, 2024

Sera Prognostics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SERA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SERASERA53Neutral$79.54M-2.90-52.54%―1.05%13.67%
BNRBNR52Neutral$131.48M-1.31-12.97%―-3.65%51.30%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ACRSACRS48Neutral$536.11M-5.75-59.20%―-59.34%57.30%
PREPRE47Neutral$276.59M-3.90-49.17%―182.05%-5.43%
BDSXBDSX44Neutral$98.47M-3.24-442.34%―31.23%48.56%
VNRXVNRX44Neutral$6.81M-0.0677.30%―134.01%32.90%

* Healthcare Sector Average

Performance Comparison

-100%0%100%200%300%SERAVNRXACRSBNRBDSXPREDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SERA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SERASera Prognostics, Inc.2.00-1.20-37.50%
VNRXVolitionRX Ltd.0.19-6.37-97.13%
ACRSAclaris Therapeutics Inc.3.380.9237.40%
BNRBurning Rock Biotech Ltd.12.50-3.53-22.02%
BDSXBiodesix, Inc.8.881.9828.70%
PREPrenetics Group Limited16.333.6228.48%

Sera Prognostics Corporate Events

Business Operations and StrategyExecutive/Board Changes

Sera Prognostics Announces CFO Transition and Succession Plan

Positive
Aug 19, 2026

On August 14, 2026, Sera Prognostics’ board appointed Scott Gleason as Chief Financial Officer and Treasurer, effective August 31, 2026, marking a planned leadership transition in the company’s finance organization. Gleason, a 47-year-old diagnostics...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026